EU Accelerated Approval Nod For Daiichi Sankyo/AZ’s Enhertu
Executive Summary
Daiichi-Sankyo has received a CHMP positive opinion for use of the antibody-drug conjugate in HER2-positive breast cancer, making this the third major market for the product.